Replimune Group's (REPL) "Hold" Rating Reiterated at Jefferies Financial Group

Key Points

• Jefferies Financial Group reiterated a Hold on Replimune and cut its price objective to $2.00 from $13.00, implying roughly a 58% downside from the prior close.
• Analyst sentiment has shifted negative overall—two Buys, four Holds and four Sells produce a MarketBeat consensus of Reduce with a $6.13 average target, and multiple firms (Piper Sandler, JPMorgan, Wedbush, HC Wainwright, Weiss) recently downgraded or lowered targets.
• Shares trade near $4.77 with a market cap of about $394M, negative EPS and a 52‑week range of $2.68–$13.24; insiders own 5.2% and institutional ownership is high (~92.5%), while an insider sold 6,500 shares under a 10b5‑1 plan.

Replimune Group (NASDAQ:REPL - Get Free Report)'s stock had its "hold" rating reaffirmed by analysts at Jefferies Financial Group in a note issued to investors on Monday,Benzinga reports. They currently have a $2.00 price objective on the stock, down from their previous price objective of $13.00. Jefferies Financial Group's price objective would indicate a potential downside of 58.08% from the stock's previous close.

Several other brokerages have also issued reports on REPL. Piper Sandler lowered Replimune Group from an "overweight" rating to a "neutral" rating and set a $4.00 target price on the stock. in a research note on Friday. JPMorgan Chase & Co. restated an "underweight" rating on shares of Replimune Group in a research note on Monday. Wedbush restated a "neutral" rating and issued a $2.00 target price (down from $19.00) on shares of Replimune Group in a research note on Monday. HC Wainwright reiterated a "sell" rating on shares of Replimune Group in a research note on Monday. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Replimune Group in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and four have given a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Reduce" and a consensus target price of $6.13.

Replimune Group Stock Performance

Shares of REPL opened at $4.77 on Monday. The firm has a market cap of $393.94 million, a PE ratio of -1.39 and a beta of 0.74. The stock's fifty day moving average price is $7.51 and its two-hundred day moving average price is $7.95. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60. Replimune Group has a 1 year low of $2.68 and a 1 year high of $13.24.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its earnings results on Tuesday, February 3rd. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.08. On average, equities research analysts forecast that Replimune Group will post -2.97 EPS for the current year.

Insider Activity

In related news, insider Christopher Sarchi sold 6,500 shares of the business's stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $8.01, for a total transaction of $52,065.00. Following the sale, the insider directly owned 151,588 shares in the company, valued at approximately $1,214,219.88. The trade was a 4.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.20% of the company's stock.

Institutional Trading of Replimune Group

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Fcpm Iii Services B.V. grew its position in Replimune Group by 6.4% during the third quarter. Fcpm Iii Services B.V. now owns 4,158,368 shares of the company's stock worth $17,424,000 after buying an additional 248,672 shares in the last quarter. Erste Asset Management GmbH grew its position in Replimune Group by 13,597.5% during the third quarter. Erste Asset Management GmbH now owns 1,630,000 shares of the company's stock worth $7,074,000 after buying an additional 1,618,100 shares in the last quarter. Braidwell LP grew its position in Replimune Group by 550.3% during the third quarter. Braidwell LP now owns 2,750,092 shares of the company's stock worth $11,523,000 after buying an additional 2,327,205 shares in the last quarter. Readystate Asset Management LP grew its position in Replimune Group by 1,296.2% during the third quarter. Readystate Asset Management LP now owns 2,621,012 shares of the company's stock worth $10,982,000 after buying an additional 2,433,292 shares in the last quarter. Finally, Quinn Opportunity Partners LLC purchased a new position in Replimune Group during the third quarter worth about $2,727,000. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.